Engineered E. coli probiotic eliminates 43% of colorectal tumors in mice
Researchers developed a genetically modified bacterium that delivers chemotherapy, immune stimulation, and checkpoint blockade directly to tumors.
What to know
- Engineered E. coli bacterium achieved 43% tumor elimination rate in mouse colorectal cancer models.
- The modified probiotic delivers three concurrent therapies: direct chemotherapy production, immune stimulation, and checkpoint blockade.
- This is early-stage research; human trials would be the next step in the development pipeline.
ScienceAlert Science journalism outlet
How it unfolded 1 development · click the chart to see its coverage articlesposts
-
1
Engineered probiotic shows 43% tumor elimination in mice
ScienceAlert reports that researchers have engineered an E. coli probiotic that wipes out 43% of colorectal tumors in mice. The engineered bacterium delivers chemotherapy directly inside the tumor, an immune stimulant, and a localized form of immune checkpoint blockade.
“The engineered E Coli packed a triple-whammy – chemotherapy produced directly inside the tumor, an immune stimulant, and a localized form of immune checkpoint blockade.”
— mvea, Reddit user · source -
first by ScienceAlert, 3d ago
-
Two fascinating cancer breakthroughs are happening at same time. First, a engineered probiotic bacteria attack 43% of colorectal tumors in mice. This bacteria can produce chemotherapy inside tumors while also activating the immune system. In mice, this treatment completely
1 more of the top 2 · 2 posts in this stretch
-
Well the country that you hate also contributes over 50% of global funding to cancer research.
-